New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 29, 2013
11:34 EDTIDRAIdera deal with NCI a positive surprise, says Piper Jaffray
Piper Jaffray views Idera's agreement with the National Cancer Institute to study TLR antagonists in lymphoma as a positive surprise and sees the potential for shares to trade higher. Piper reiterates its Overweight rating and $2.60 target on Idera.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 23, 2015
09:27 EDTIDRAIdera Pharmaceuticals Chief Medical Officer resigns
Idera Pharmaceuticals disclosed in a regulatory filing that Louis Brenner, M.D. resigned his positions as senior VP and Chief Medical Officer of Idera to accept a new role as the Chief Operating Officer of a privately-held biotechnology company. This change will become effective April 3.
March 12, 2015
08:19 EDTIDRAIdera Pharmaceuticals reports Q4 EPS (14c), two estimates (11c)
Reports Q4 revenue $2K, two estimates $60.00K.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use